Jamie Christensen - 29 Dec 2023 Form 4 Insider Report for Mirati Therapeutics, Inc.

Role
EVP & Chief Scientific Officer
Signature
/s/ John Moriarty, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
29 Dec 2023
Net transactions value
+$999,984
Form type
4
Filing time
03 Jan 2024, 18:05:42 UTC
Previous filing
19 Dec 2023
Next filing
05 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRTX Common Stock Award $999,984 +17,021 +12% $58.75 158,666 29 Dec 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested.